
Aligos Therapeutics ALGS
$ 8.36
4.89%
Annual report 2025
added 03-05-2026
Aligos Therapeutics Total Current Liabilities 2011-2026 | ALGS
Annual Total Current Liabilities Aligos Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 M | 21.7 M | 23.9 M | 33.1 M | 39 M | 30.3 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 39 M | 21.2 M | 28.2 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akebia Therapeutics
AKBA
|
163 M | $ 1.35 | -2.17 % | $ 347 M | ||
|
Akari Therapeutics, Plc
AKTX
|
12.4 M | $ 3.5 | -21.7 % | $ 236 B | ||
|
Aldeyra Therapeutics
ALDX
|
27.8 M | $ 1.58 | -4.82 % | $ 94.9 M | ||
|
Alnylam Pharmaceuticals
ALNY
|
1.47 B | $ 330.71 | 3.72 % | $ 43.3 B | ||
|
Altimmune
ALT
|
15 M | $ 3.47 | 3.89 % | $ 306 M | ||
|
ALX Oncology Holdings
ALXO
|
24.6 M | $ 1.98 | 0.25 % | $ 106 M | ||
|
Amgen
AMGN
|
25.5 B | $ 346.45 | -0.43 % | $ 186 B | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Amneal Pharmaceuticals
AMRX
|
882 M | $ 12.37 | -0.92 % | $ 3.88 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Anika Therapeutics
ANIK
|
31.1 M | $ 15.0 | 1.32 % | $ 220 M | ||
|
ANI Pharmaceuticals
ANIP
|
194 M | $ 76.34 | 2.87 % | $ 1.47 B | ||
|
Annexon
ANNX
|
42.6 M | $ 5.64 | 2.45 % | $ 875 M | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.92 | -1.11 % | $ 5.02 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Aprea Therapeutics
APRE
|
2.76 M | $ 0.73 | 2.63 % | $ 4.77 M | ||
|
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.15 | 0.48 % | $ 444 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 8.43 | 4.98 % | $ 231 M | ||
|
Ardelyx
ARDX
|
88.6 M | $ 6.08 | 2.27 % | $ 1.47 B | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
142 M | $ 11.11 | 2.4 % | $ 788 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
195 M | $ 61.57 | 0.88 % | $ 8.24 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Assembly Biosciences
ASMB
|
48.8 M | $ 30.01 | 3.43 % | $ 336 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Actinium Pharmaceuticals
ATNM
|
7.97 M | $ 1.14 | 16.28 % | $ 35.6 M | ||
|
Atossa Therapeutics
ATOS
|
8.26 M | $ 5.21 | -2.89 % | $ 44.9 M | ||
|
Atara Biotherapeutics
ATRA
|
14.9 M | $ 5.03 | 0.7 % | $ 63.1 M | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
93.7 M | $ 16.04 | 2.75 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.42 | 0.35 % | $ 378 M | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
6.18 M | - | 10.36 % | $ 9.8 M |